So I thought I would try to estimate revenue for FY 2020.I will...

So I thought I would try to estimate revenue for FY 2020.
I will try doing this with all that is available to market at this current time and I may have to leave some things to the imagination.

Neurio1: Captain & Crew Appointment..

The announcement was made 22 feb 2019 stating they would purchase 300000 units for the first year and 500000 units for the second year. announcement was made close to mid FY in order to determine the closest estimate I will take 50% from first year and 50% from second year. 150000+250000= 400000. at $40 a piece that would be 16m.

Ref: Ann: Sole agency, Japan and Korea.

Neurio2: Health one agreement.

The announcement was made 5 June 2019, stating health one would provide a profit of 1.5m for the year. judging by sunya 30% margin for FY 2019, to me I would estimate that as a gross 4.5m

Ref: Ann: Distribution agreement with health one.

Neurio3: agreement with guangzhou nuirui.

The announcement was made 1 April 2019 stating each year they have agreed to purchase 100000 tins. 100000x$40 a piece =4m

Ref: Ann: distribution agreement with guangzhou nuirui.

Neurio4: agreement with cyclone.

This announcement was announced close to mid year on 14 nov 2019. it stated cyclone had completed selling 7.5m of neurio product. it's aim for second yeast was 17m. as it was announced mid year in order to get the best estimate I will take half of the first year plus half of the second year. 3.75+8.5=12.25m

Ref: Ann: New distribution agreement signed at ciie.

Neurio5: Distribution agreement kigobaby.

This announcement stated the company would have a 100000 deposit followed by reoccurring payments of 960000 per month, 4 months till in of FY= 4.1m

Ref: Ann: New China distribution agreement for a single NEURIO product.

ANMA: Third party manufacturing agreement.

This announcement stated from feb 2020 ANMA would receive 1.8m for manufacturing beta a2 product.

1.8+4.1+12.25+4+4.5+16=42.65m. roughly we own 50% of most subsidiary's so 21.3m is for jat.

Parts of the puzzle that aren't evaluable to a decent estimate although proving to be significant assets.

These will have to be left to the imagination.

Products sold by Neurios personal profiles on JD.com and rest of e-commerce sites.

The impact of partnering with Sinopharm. judging by the fact Sinopharm brings in over 51b per year I'd say the relationship is quite valuable.

The impact of distribution agreement with ocker products.

The impacts of distribution agreement with Hit crown co.

Golden Koala products sold on JD and others.

Still so much I have missed out on that I have come across that shows it will bring value to the company. but this is about all I can be bothered with.

So from that hopefully you can se at a minimum we are looking at, is growing from 5m from infant formula to 20m at end of FY 2020 along with at least 59m from green forest.
I'd also expect the unevaluables to nearly double the formula revenue.
Margins: Taking into consideration we commenced production in our own factory in this FY I'd expect over 30% considering margins for formula were 29% last year without the factory.

GL DYOR